Vasopressin and oxytocin receptors
More information on this family may be found on the IUPHAR-DB family and introduction pages.
Vasopressin (AVP) and oxytocin (OT) receptors (nomenclature as agreed by NC-IUPHAR Subcommittee on vasopressin and oxytoxcin receptors) are activated by the endogenous cyclic nonapeptides AVP and oxytocin (OT). These peptides are derived from precursors (ENSG00000101200 and ENSG00000101405 respectively), which also produce neurophysins.
Unless otherwise stated all data refer to the human proteins. Gene information is provided for human (Hs), mouse (Mm) and rat (Rn).
Receptors 
|
||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||
|
Gimpl, G; Reitz, J; Brauer, S; Trossen, C. (2008) Oxytocin receptors: ligand binding, signalling and cholesterol dependence. Prog. Brain Res., 170: 193-204. [PMID:18655883]
Lee, HJ; Macbeth, AH; Pagani, JH; Young, WS. (2009) Oxytocin: the great facilitator of life. Prog. Neurobiol., 88 (2): 127-51. [PMID:19482229]
Manning, M; Stoev, S; Chini, B; Durroux, T; Mouillac, B; Guillon, G. (2008) Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog. Brain Res., 170: 473-512. [PMID:18655903]
McGregor, IS; Callaghan, PD; Hunt, GE. (2008) From ultrasocial to antisocial: a role for oxytocin in the acute reinforcing effects and long-term adverse consequences of drug use?. Br. J. Pharmacol., 154 (2): 358-68. [PMID:18475254]
Oghlakian, G; Klapholz, M. (2009) Vasopressin and vasopressin receptor antagonists in heart failure. Cardiol Rev, 17 (1): 10-5. [PMID:19092365]
Roper, J; O'Carroll, AM; Young, W; Lolait, S. (2011) The vasopressin Avpr1b receptor: molecular and pharmacological studies. Stress, 14 (1): 98-115. [PMID:20828336]
Veeraveedu, PT; Palaniyandi, SS; Yamaguchi, K; Komai, Y; Thandavarayan, RA; Sukumaran, V; Watanabe, K. (2010) Arginine vasopressin receptor antagonists (vaptans): pharmacological tools and potential therapeutic agents. Drug Discov. Today, 15 (19-20): 826-41. [PMID:20708094]
1. Akerlund, M., Bossmar, T., Brouard, R., Kostrzewska, A., Laudanski, T., Lemancewicz, A., Serradeil-Le Gal, C. and Steinwall, M. (1999) Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women. Br J Obstet Gynaecol, 106: 1047-1053. [PMID:10519430]
2. Ala, Y., Morin, D., Mouillac, B., Sabatier, N., Vargas, R., Cotte, N., Déchaux, M., Antignac, C., Arthus, M. F., Lonergan, M., Turner, M. S., Balestre, M. N., Alonso, G., Hibert, M., Barberis, C., Hendy, G. N., Bichet, D. G. and Jard, S. (1998) Functional studies of twelve mutant V2 vasopressin receptors related to nephrogenic diabetes insipidus: molecular basis of a mild clinical phenotype. J Am Soc Nephrol, 9: 1861-1872. [PMID:9773787]
3. Albright, JD; Reich, MF; Delos Santos, EG; Dusza, JP; Sum, FW; Venkatesan, AM; Coupet, J; Chan, PS; Ru, X; Mazandarani, H; et al.. (1998) 5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors. J. Med. Chem., 41 (14): 2442-4. [PMID:9651149]
4. Andres, M., Trueba, M. and Guillon, G. (2002) Pharmacological characterization of F-180: a selective human V1a vasopressin receptor agonist of higly affinity. Br J Pharmacol, 135: 1828-1836. [PMID:11934825]
5. Bell, I. M., Erb, J. M., Freidinger, R. M., Gallicchio, S. N., Guare, J. P., Guidotti, M. T., Halpin, R. A., Hobbs, D. W., Homnick, C. F., Kuo, M. S., Lis, E. V., Mathre, D. J., Michelson, S. R., Pawluczyk, J. M., Pettibone, D. J., Reiss, D. R., Vickers, S., Williams, P. D. and Woyden, C. J. (1998) Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines. J Med Chem, 41: 2146-2163. [PMID:9622556]
6. Bichet, D. G., Turner, M. and Morin, D. (1998) Vasopressin receptor mutations causing nephrogenic diabetes insipidus. Proc Assoc Am Physicians, 110: 387-394. [PMID:9756088]
7. Breton, C., Chellil, H., Kabbaj-Benmansour, M., Carnazzi, E., Seyer, R., Phalipou, S., Morin, D., Durroux, T., Zingg, H. H., Barberis, C. and Mouillac, B. (2001) Direct identification of human oxytocin receptor-binding domains using a photoactivatable cyclic peptide antagonist: comparison with the human V1a vasopressin receptor. J Biol Chem, 276: 26931-26941. [PMID:11337500]
8. Cheng, L. L., Stoev, S., Manning, M., Derick, S., Pena, A., Mimoun, M. B. and Guillon, G. (2004) Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem, 47: 2375-2388. [PMID:15084136]
9. Chini, B., Mouillac, B., Ala, Y., Balestre, M. N., Trumpp-Kallmeyer, S., Hoflack, J., Elands, J., Hibert, M., Manning, M., Jard, S. et al.. (1995) Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptor. The EMBO Journal., 14: 2176-2182. [PMID:7774575]
10. Chini, B., Mouillac, B., Balestre, M-N., Trumpp-Kallmeyer, S., Hoflack, J., Hibert, M., Andriolo, M., Pupier, S., Jard, S. and Barberis, C. (1996) Two aromatic residues regulate the response of the human oxytocin receptor to the partial agonist arginine vasopressin. FEBS letters., 397: 201-206. [PMID:8955347]
11. Chini, B; Chinol, M; Cassoni, P; Papi, S; Reversi, A; Areces, L; Marrocco, T; Paganelli, G; Manning, M; Bussolati, G. (2003) Improved radiotracing of oxytocin receptor-expressing tumours using the new [111In]-DOTA-Lys8-deamino-vasotocin analogue. Br. J. Cancer, 89 (5): 930-6. [PMID:12942128]
12. Cotte, N., Balestre, M. N., Aumelas, A., Mahe, E., Phalipou, S., Morin, D., Hibert, M., Manning, M., Durroux, T., Barberis, C. and Mouillac, B. (2000) Conserved aromatic residues in the transmembrane region VI of the V1a vasopressin receptor differentiate agonist vs. antagonist ligand binding. Eur J Biochem, 267: 4253-4263. [PMID:10866830]
13. Cotte, N., Balestre, M. N., Phalipou, S., Hibert, M., Manning, M., Barberis, C. and Mouillac, B. (1998) Identification of residues responsible for the selective binding of peptide antagonists and agonists in the V2 vasopressin receptor. J Biol Chem, 273: 29462-29468. [PMID:9792651]
14. Derick, S., Cheng, L. L., Stoev, S., Voirol, M. J., Ben Mimoun, M., Andres, M., Gaillard, R., Guillon, G. and Manning, M. (2002) [1-Deamino-4-Cyclohexylalanine]Arginine vasopressin: a potent and specific agonist for vasopressin V1b receptors. Endocrinology., 143: 4655-4664. [PMID:12446593]
15. Elands, J; Barberis, C; Jard, S. (1988) [3H]-[Thr4,Gly7]OT: a highly selective ligand for central and peripheral OT receptors. Am. J. Physiol., 254 (1 Pt 1): E31-8. [PMID:2827511]
16. Failli, AA; Shumsky, JS; Steffan, RJ; Caggiano, TJ; Williams, DK; Trybulski, EJ; Ning, X; Lock, Y; Tanikella, T; Hartmann, D; et al.. (2006) Pyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists. Bioorg. Med. Chem. Lett., 16 (4): 954-9. [PMID:16297621]
17. Fuchs, A. R., Fuchs, F., Husslein, P., Soloff, M. S. and Fernstrom, M. J. (1982) Oxytocin receptors and human parturition: a dual role for oxytocin in the initiation of labor. Science, 215: 1396-1398. [PMID:6278592]
18. Griebel, G., Simiand, J., Serradeil-Le Gal, C., Wagnon, J., Pascal, M., Scatton, B., Maffrand, J. P. and Soubrie, P. (2002) Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci U S A, 99: 6370-6375. [PMID:11959912]
19. Griffante, C., Green, A., Curcuruto, O., Haslam, C. P., Dickinson, B. A. and Arban, R. (2005) Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist. Br J Pharmacol, 146: 744-751. [PMID:16158071]
20. Jasper, J. R., Harrell, C. M., O'Brien, J. A. and Pettibone, D. J. (1995) Characterization of the human oxytocin receptor stably expressed in 293 human embryonic kidney cells. Life Sci, 57: 2253-2261. [PMID:7475979]
21. Kimura, T., Makino, Y., Saji, F., Takemura, M., Inoue, T., Kikuchi, T., Kubota, Y., Azuma, C., Nobunaga, T. and Tokugawa, Y. (1994) Molecular characterization of a cloned human oxytocin receptor. Eur J Endocrinol, 131: 385-390. [PMID:7921228]
22. Lemaire, W; O'Brien, JA; Burno, M; Chaudhary, AG; Dean, DC; Williams, PD; Freidinger, RM; Pettibone, DJ; Williams, DL. (2002) A nonpeptide oxytocin receptor antagonist radioligand highly selective for human receptors. Eur. J. Pharmacol., 450 (1): 19-28. [PMID:12176104]
23. Nakamura, S., Yamamura, Y., Itoh, S., Hirano, T., Tsujimae, K., Aoyama, M., Kondo, K., Ogawa, H., Shinohara, T., Kan, K., Tanada, Y., Teramoto, S., Sumida, T., Nakayama, S., Sekiguchi, K., Kambe, T., Tsujimoto, G., Mori, T. and Tominaga, M. (2000) Characterization of a novel nonpeptide vasopressin V(2)-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes. Br J Pharmacol, 129: 1700-1706. [PMID:10780976]
24. Pena, A., Murat, B., Trueba, M., Ventura, M. A., Wo, N. C., Szeto, H. H., Cheng, L. L., Stoev, S., Guillon, G. and Manning, M. (2007) Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8. J Med Chem, 50: 835-847. [PMID:17300166]
25. Phalipou, S., Cotte, N., Carnazzi, E., Seyer, R., Mahe, E., Jard, S. and Barberis, C. (1997) Mapping peptide binding domains of the human V1a vasopressin receptor with a photoactivatable linear peptide antagonist. J Biol Chem, 272: 26536-26544. [PMID:9334232]
26. Rene, P., Lenne, F., Ventura, M. A., Bertagna, X. and de Keyzer, Y. (2000) Nucleotide sequence and structural organization of the human vasopressin pituitary receptor (V3) gene. Gene, 241: 57-64. [PMID:10607899]
27. Saito, M., Tahara, A. and Sugimoto, T. (1997) 1-desamino-8-D-arginine vasopressin (DDAVP) as an agonist on V1b vasopressin receptor. Biochem Pharmacol, 53: 1711-1717. [PMID:9264324]
28. Serradeil-Le Gal, C., Lacour, C., Valette, G., Garcia, G., Foulon, L., Galindo, G., Bankir, L., Pouzet, B., Guillon, G., Barberis, C., Chicot, D., Jard, S., Vilain, P., Garcia, C., Marty, E., Raufaste, D., Brossard, G., Nisato, D., Maffrand, J. P. and Le Fur, G. (1996) Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J Clin Invest, 98: 2729-2738. [PMID:8981918]
29. Serradeil-Le Gal, C., Raufaste, D., Double-Cazanave, E., Guillon, G., Garcia, C., Pascal, M. and Maffrand, J. P. (2000) Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463. Kidney Int, 58: 1613-1622. [PMID:11012895]
30. Serradeil-Le Gal, C., Valette, G., Foulon, L., Germain, G., Advenier, C., Naline, E., Bardou, M., Martinolle, J-P., Pouzet, B., Raufaste, D., Garcia, C., Double-Cazenave, E., Pauly, M., Pascal, M., Barbier, A., Scatton, B., Maffrand, J-P. and Le Fur, G. (2004) SSR126768A (4-Chloro-3-[(3R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2oxo-2,3-dihydro-1H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)-benzamidine, hydrochloride): a new selective and orally active oxytocin receptor antagonist for the prevention of preterm labor. J Pharmacol Exp Therap, 309: 414-424. [PMID:14722330]
31. Serradeil-Le Gal, C., Wagnon, J., Simiand, J., Griebel, G., Lacour, C., Guillon, G., Barberis, C., Brossard, G., Soubrie, P., Nisato, D., Pascal, M., Pruss, R., Scatton, B., Maffrand, J. P. and Le Fur, G. (2002) Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. J Pharmacol Exp Ther, 300: 1122-1130. [PMID:11861823]
32. Tahara, A., Saito, M., Sugimoto, J., Tomura, Y., Wada, K. I., Kusayama, T., Tsukada, J., Ishii, I., Yatsu, T., Uchida, W. and Tanaka, A. (1998) Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in chinese hamster ovary cells. Br J Pharmacol, 125: 1463-1470. [PMID:9884074]
33. Tahara, A., Saito, M., Sugimoto, T., Tomura, Y., Wada, K., Kusayama, T., Tsukada, J., Ishii, N., Yatsu, T., Uchida, W. and Tanaka, A. (1998) Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist. Naunyn Schmiedebergs Arch Pharmacol, 357: 63-69. [PMID:9459574]
34. Thibonnier, M., Auzan, C., Madhun, Z., Wilkins, P., Berti-Mattera, L. and Clauser, E. (1994) Molecular cloning, sequencing, and functional expression of a cDNA encoding thehuman V1a vasopressin receptor. J Biol Chem, 269: 3304-3310. [PMID:8106369]
35. Thibonnier, M., Preston, J. A., Dulin, N., Wilkins, P. L., Berti-Matera, L. N. and Mattera, R. (1997) The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. Endocrinology., 138: 4109-4122. [PMID:9322919]
36. Tsukada, J., Tahara, A., Tomura, Y., Wada, Ki., Kusayama, T., Ishii, N., Yatsu, T., Uchida, W., Taniguchi, N. and Tanaka, A. (2001) Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells. Br J Pharmacol., 133: 746-754. [PMID:11429400]
37. Yamamura, Y., Nakamura, S., Itoh, S., Hirano, T., Onogawa, T., Yamashita, T., Yamada, Y., Tsujimae, K., Aoyama, M., Kotosai, K., Ogawa, H., Yamashita, H., Kondo, K., Tominaga, M., Tsujimoto, G. and Mori, T. (1998) OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther, 287: 860-867. [PMID:9864265]
38. Yamamura, Y; Ogawa, H; Yamashita, H; Chihara, T; Miyamoto, H; Nakamura, S; Onogawa, T; Yamashita, T; Hosokawa, T; Mori, T. (1992) Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br. J. Pharmacol., 105 (4): 787-91. [PMID:1387020]
|
 @GuidetoPHARM  Like us on Facebook Privacy and Cookie Policy |
The V2 receptor exhibits marked species differences, such that many ligands (d(CH2)5[D-Ile2,Ile4]AVP and [3H]desGly-NH2[D-Ile2,Ile4]VP) exhibit low affinity at human V2 receptors [2]. Similarly, [3H]d[D-Arg8]VP is V2 selective in the rat, not in the human [27]. The gene encoding the V2 receptor is polymorphic in man, underlying nephrogenic diabetes insipidus [6]. conivaptan display high affinity for both human V1a and V2 receptors [33]. d[Cha4]AVP is selective only for the human and bovine V1b receptors [14], while d[Leu4]LVP has high affinity for the rat V1b receptor [24].